Related Experiment Video
Updated: May 24, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials
Minwen Xu1, Gaohui Yuan, Fanping Wei
1Department of Cardiology, Huzhou Central Hospital, Huzhou, Zhejiang, China.
Insights
Atorvastatin significantly reduced mortality and hospitalizations in chronic heart failure (CHF) patients. This meta-analysis suggests atorvastatin benefits, unlike rosuvastatin, warranting further investigation in large trials.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Rosuvastatin trials showed disappointing results in chronic heart failure (CHF) patients.
- Uncertainty exists regarding the efficacy of other statins in CHF.
- This study investigates atorvastatin's efficacy in CHF patients.
Purpose of the Study:
- To evaluate the clinical efficacy of atorvastatin in patients with chronic heart failure (CHF).
- To determine if atorvastatin offers benefits in CHF where rosuvastatin did not.
Main Methods:
- A meta-analysis of randomized controlled trials (RCTs) was conducted.
- Searched electronic databases up to January 2010 for eligible trials.
- Included RCTs comparing atorvastatin versus placebo in CHF patients.
Main Results:
- Seven trials with 540 patients met inclusion criteria.
- Atorvastatin significantly reduced all-cause mortality (OR 0.39, P = 0.002).
- Significant reductions observed in cardiovascular mortality, sudden cardiac death, and CHF hospitalizations.
Conclusions:
- Atorvastatin treatment is effective in reducing mortality and hospitalizations in CHF patients.
- Findings suggest atorvastatin may be beneficial in CHF.
- Further large trials are needed to confirm atorvastatin's benefits in CHF.
Introduction:
Recent large clinical trials have yielded disappointing results of rosuvastatin in the chronic heart failure (CHF) population. The question that remains is whether these results of rosuvastatin studies could be extended to other statins. Therefore, we performed a meta-analysis based on all currently available randomized controlled trials (RCTs) to evaluate the clinical efficacy of atorvastatin in CHF patients.
Material And Methods:
The published literature was scanned by formal searches of electronic databases up to January 2010. RCTs were eligible for inclusion if they compared atorvastatin versus placebo treatment in patients with CHF and reported the clinical outcomes.
Results:
Pre-specified criteria were met by 7 trials involving 540 patients. The primary endpoint, all-cause mortality, was significantly reduced with atorvastatin therapy compared with placebo in CHF patients (odds ratio [OR] 0.39, P = 0.002), with similar results in cardiovascular mortality (OR 0.28, P = 0.002) and sudden cardiac death (OR 0.24, P = 0.01). There was also a significant decrease in hospitalization for worsening CHF with atorvastatin therapy compared with placebo (OR 0.30, P < 0.001).
Conclusions:
This meta-analysis suggests the effectiveness of atorvastatin treatment in reducing the risks of all-cause mortality and worsening CHF hospitalization in patients with CHF. Further large, well-conducted randomized trials are needed to confirm the benefits of atorvastatin or other statins for CHF relative to placebo or rosuvastatin.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management
01:26Heart Failure III: Clinical Manifestations
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inotropic Agents